To DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:
the identification of patients at high risk of diabetes complications
the monitoring of the complications' progression and patients‘ response to therapy
To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.
Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.